← Oncology Approval Tracker

FDA DECISION ·

Enhertu

fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo

FDA approvalNew or expanded indicationGastric and gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with HER2-positive gastric or gastroesophageal junction adenocarcinoma that is locally advanced or metastatic, after a trastuzumab-based regimen.

LAMPGEN ANALYSIS

Why it matters

The approval brings a HER2-directed antibody-drug conjugate into previously treated gastric and gastroesophageal junction cancer.

What research teams should watch

Document the gastric-specific HER2 result and earlier trastuzumab exposure, and plan pulmonary adverse event follow-up.

PRIMARY RECORDS

Sources